News / Korea / yonhap_finance
FSS to Host Briefing Sessions on Enhanced Disclosure Guidelines for Pharma and Biotech Firms
Health Technology · Biotechnology · yonhap_finance · 2026-08-24
The Financial Supervisory Service will hold a series of briefings next month to guide pharmaceutical and biotech companies on new, stricter disclosure requirements.
What Happened
Briefing Schedule: The Financial Supervisory Service (FSS) has announced a series of four briefing sessions scheduled for next month to ensure the smooth implementation of new disclosure requirements for the pharmaceutical and biotech sectors. These sessions will be tailored to specific market participants, including KOSDAQ-listed firms, underwriters, pre-IPO companies, and KOSPI-listed entities.
Enhanced Disclosure Standards: Under the new guidelines, companies are now required to provide detailed disclosures regarding key assumptions in valuation, such as projected market size, clinical trial success probabilities, and regulatory approval risks. Furthermore, the scope of disclosures for technology transfer agreements has been expanded to include contract structures and simplified explanations of technical terminology.
Reducing Operational Friction: The FSS aims to minimize administrative burdens and potential delays in capital raising by ensuring that market participants fully understand the updated standards. By clarifying expectations early, the regulator hopes to reduce the frequency of correction requests and improve overall compliance efficiency.
Ongoing Support: The guidelines presented during these sessions will be made available on the FSS website for future reference. This initiative is part of a broader effort to enhance transparency and investor confidence in the pharmaceutical and biotechnology industries.